- Home
- DSGN vs JRS Comparison
DSGN vs JRS Comparison
Compare DSGN & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- JRS
- Stock Information
- Founded
- DSGN 2017
- JRS 2001
- Country
- DSGN United States
- JRS United States
- Employees
- DSGN N/A
- JRS N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- JRS Finance/Investors Services
- Sector
- DSGN Health Care
- JRS Finance
- Exchange
- DSGN Nasdaq
- JRS Nasdaq
- Market Cap
- DSGN 208.9M
- JRS 224.5M
- IPO Year
- DSGN 2021
- JRS N/A
- Fundamental
- Price
- DSGN $5.26
- JRS $8.02
- Analyst Decision
- DSGN
- JRS
- Analyst Count
- DSGN 0
- JRS 0
- Target Price
- DSGN N/A
- JRS N/A
- AVG Volume (30 Days)
- DSGN 141.5K
- JRS 86.6K
- Earning Date
- DSGN 08-07-2025
- JRS 01-01-0001
- Dividend Yield
- DSGN N/A
- JRS 8.87%
- EPS Growth
- DSGN N/A
- JRS N/A
- EPS
- DSGN N/A
- JRS N/A
- Revenue
- DSGN N/A
- JRS N/A
- Revenue This Year
- DSGN N/A
- JRS N/A
- Revenue Next Year
- DSGN N/A
- JRS N/A
- P/E Ratio
- DSGN N/A
- JRS N/A
- Revenue Growth
- DSGN N/A
- JRS N/A
- 52 Week Low
- DSGN $2.60
- JRS $5.95
- 52 Week High
- DSGN $7.77
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- JRS 66.64
- Support Level
- DSGN $4.68
- JRS $7.77
- Resistance Level
- DSGN $5.60
- JRS $7.87
- Average True Range (ATR)
- DSGN 0.39
- JRS 0.10
- MACD
- DSGN 0.04
- JRS 0.04
- Stochastic Oscillator
- DSGN 79.95
- JRS 87.36
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.